TOPICAL USE OF TERBINAFINE AND SIMILAR COMPOUNDS FOR INFLAMMATORY OCULAR CONDITIONS
The present disclosure provides methods of treating an inflammatory ocular condition, the methods comprising topically administering to an ocular surface of a subject in need thereof a composition comprising an allylamine, for example, terbinafine, naftifine, or a pharmaceutically acceptable salt, conjugate or derivative thereof. The present disclosure also provides methods of treating an ocular condition selected from keratitis, chronic conjunctivitis, allergic conjunctivitis, dry-eye disease, blepharitis, uveitis or combinations thereof, the methods comprising topically administering to an ocular surface of a subject in need thereof a composition comprising an allylamine, for example, terbinafine or pharmaceutically acceptable salt, conjugate or derivative thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 28. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ELKOSHI ZEEV [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-28, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 |
|---|
| Patentnummer: |
WO2023183603 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018258824 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018258824 | ||
| 003 | DE-627 | ||
| 005 | 20231229104620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231020s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018258824 | ||
| 035 | |a (EPA)WO2023183603 | ||
| 035 | |a (EPA)88102139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ELKOSHI ZEEV |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TOPICAL USE OF TERBINAFINE AND SIMILAR COMPOUNDS FOR INFLAMMATORY OCULAR CONDITIONS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-28, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 | ||
| 520 | |a The present disclosure provides methods of treating an inflammatory ocular condition, the methods comprising topically administering to an ocular surface of a subject in need thereof a composition comprising an allylamine, for example, terbinafine, naftifine, or a pharmaceutically acceptable salt, conjugate or derivative thereof. The present disclosure also provides methods of treating an ocular condition selected from keratitis, chronic conjunctivitis, allergic conjunctivitis, dry-eye disease, blepharitis, uveitis or combinations thereof, the methods comprising topically administering to an ocular surface of a subject in need thereof a composition comprising an allylamine, for example, terbinafine or pharmaceutically acceptable salt, conjugate or derivative thereof. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SCHLINGER RON |4 aut | |
| 700 | 0 | |a AVRAMOFF AVI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 28. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88102139/publication/WO2023183603A1?q=WO2023183603 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 28 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 09 | ||